TRINITY BIOMEDICAL SCIENCES INSTITUTE (TBSI) .

The Trinity Biomedical Sciences Institute (TBSI) is an environment where innovative and interdisciplinary approaches are leading to scientific discoveries of biomedical importance, ultimately giving rise to better patient care. The mechanistic basis for a whole range of diseases is under investigation, including infectious and inflammatory diseases such as arthritis and Type 2 diabetes, neurological diseases such as motor neuron disease and multiple sclerosis, and different forms of cancer.

Our focus is on outstanding discovery, since there remains a major unmet medical need for the treatment of these diseases and our understanding of the molecular basis of many diseases remains limited.

TBSI also houses all of our preclinical training in our medical degree. We aim to foster a spirit of interaction and exploration on the frontiers of biomedical research, such that truly ground-breaking discoveries can be made. We have established 3 centres in TBSI – Centre for Cancer Drug Discovery (C2D2), Medical Device Technologies (CMDT) and Centre for Translational Medicine . We are also supporting spin out companies such as Trimod Therapeutics, and are working with several pharmaceutical and medical device companies.

The primary mission of TBSI is to make fundamental discoveries in biomedical research. TBSI is an environment where innovative and interdisciplinary approaches lead to scientific discoveries of biomedical importance, ultimately giving rise to better patient care. Occupancy began in 2011 and we now have over 550 researchers, working towards discoveries of direct relevance to human diseases in a multi-disciplinary environment. Recent years have seen strong funding growth (research awards in excess of €75m since building occupancy) and important discoveries in areas such as cancer, asthma, Type-2 diabetes, Age-related macular degeneration, infectious diseases such as hepatitis C and motor neuron disease. Discoveries have been published in journals of the highest rank internationally, with publications in Nature (twelve publications), Science, Cell, Nature Medicine, Nature Immunology, Nature Neuroscience and The Lancet. There have been more than 1600 publications, including 12 in Nature.

The building has an area of 35,000m2 of which 21,000m2 are used for research and teaching. TBSI houses 75 PIs and research staff from:

  •  The School of Biochemistry and Immunology (100% located in TBSI)
  •  The School of Chemistry
  •  The Trinity Centre for Bioengineering
  •  The School of Pharmacy and Pharmaceutical Sciences
  •  The School of Medicine

Whilst the activities of the research groups cover a wide range of research topics, they all have relevance for Biomedical Sciences. Translational activities are facilitated through strong relationships with hospitals and the presence of Trinity clinical personnel and research laboratories on hospital sites.